Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Featured Stories

Pharma Q1 Results Preview: Shire, AbbVie, Bristol, Sanofi, Allergan

All eyes are on Shire in its first quarter of reporting separate figures for its neuroscience division as Takeda ramps up the takeover pressure, while BMS, AbbVie, Sanofi, and Allergan primes pipeline for revenue growth.

Sales & Earnings Companies Commercial

Takeda Closes In On Shire With Revised £49/Share Offer

Takeda further ups its offer for Shire to around £49 per share, which Shire’s board has said it is willing to recommend to shareholders, although any final deal remains subject to conditions.

Japan Commercial M & A

Sweet Enough? Takeda Raises, Adds Cash To Shire Offer

Takeda has further bumped up its offer for acquisition target Shire, raising the per share price and cash component, in what the Japanese firm says is a “compelling” proposal worth well over $60bn. Will it be fourth time lucky?

Japan Commercial M & A

 Recent Tweets from Scrip


Commercial Explore this Topic

Set Alert for Commercial

Biogen's Spinraza Sales Plateau; The Challenge Is Keeping Up With The Successful Launch

Sales of Biogen's blockbuster rare disease drug moderated in the first quarter as the company worked through the bolus of urgent infant and pediatric patients awaiting treatment in the US.

Sales & Earnings Neurology Business Strategies

Lilly Rides To Solid First Quarter On Diabetes, Newer Products

Smarting from a disappointing advisory committee review for baricitinib, Lilly pointed to the strong first quarter performance of its drugs launched since 2014, especially Trulicity.
Sales & Earnings Business Strategies Metabolic Disorders

Deal Watch Asia Focus: Pfenex Licenses Asian Rights To Forteo Copy To NT Pharma Group

Otsuka obtains Japanese rights to two cancer gene therapy candidates from Takara. GlaxoSmithKline extends its protein degradation collaboration with Kymera.
Commercial Business Strategies

Circassia Puts Aside R&D, Aims To Grow Commercial Platform

UK biotech Circassia puts Phase III cat allergy vaccine failure behind it and intends to move forward with building its commercial platform, and sales, in the respiratory sector.


Business Strategies Respiratory

TRPharm Chair: 'Dr Reddy's Partnership Is Key To International Expansion'

Turkey's TRPharm, in partnership with India's Dr Reddy's, has become the first company to gain a license for a biosimilar product in Turkey. Chairman Mehmet Göker spoke to Scrip about the company's international expansion plans.

Turkey Biosimilars

Spotlight On Israel: Compugen Comes Forth

Compugen, a predictive drug discovery and development company, plays an important role within Israel's biopharma sector as one of the oldest businesses in an immature market. Building on its 25-year history, the company is about to embark on a new challenge: clinical development.

Israel Business Strategies

Oncology Venture Differentiates Using Big Data Systems Biology

With six oncology assets in Phase II/III ready for outlicensing, Oncology Venture is now looking to take additional programs on board.

Business Strategies Financing

Deal Watch: Fresenius Drops Bid For Akorn, Citing Data-Integrity Concerns

Janssen and Bristol team to develop next-generation oral anticoagulant, while UCB buys Proximagen's nasal spray candidate and Duke spinout focused on genomics.
Business Strategies Deals

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

Lilly May Need To Reassess Baricitinib Market After FDA Advisory Committee

During a mixed review by the US FDA's Arthritis Advisory Committee, panelists suggested that risks potentially associated with Lilly/Incyte's JAK inhibitor would be acceptable for a more limited patient population.

Advisory Committees Drug Safety Inflammation

Kaesong Complex A Starting Point For Two Koreas' Healthcare Cooperation?

As political talks gain momentum, the Kaesong Industrial Complex in North Korea could be the starting point of possible healthcare cooperation with the South, once the relationship between the two countries improves, a South Korean official report suggests. 

South Korea North Korea

Synthetic Biologics’ Ribaxamase Setback Shows Difficulty Of C. Difficile Development

Company believes there is a path forward for developing ribaxamase in Phase III, based on discussions with the FDA, but deaths in Phase II meant loss of breakthrough designation.

Clinical Trials Drug Approval Standards

China Vs Cancer: An Infographic Snapshot

Cancer cases are rising in China, with larger increases for certain types including thyroid and pancreatic. To combat the rising tide, the government will implement zero tariffs on imported anticancer drugs  from May.

Cancer China

Research & Development Explore this Topic

Set Alert for Research & Development

ARCTIC Chill Descends On AstraZeneca's Imfinzi/Treme Combo In NSCLC

Failure of the ARCTIC study was considered likely and will do little to dent Imfinzi's overall sales prospects but cools sentiment on the CTLA4 inhibitor tremelimumab.

Clinical Trials Research & Development Cancer

QUADRA Supports Broader Use For Tesaro's PARP Inhibitor Zejula

Study in late-line use of heavily pretreated ovarian cancer may bring labeling closer in line with competitors, yet with limited commercial impact, analysts say.

Clinical Trials Research & Development

Zerhouni Retires, Sanofi's New R&D Chief John Reed Brings Early Research Experience From Roche

Sanofi's longtime head of R&D Elias Zerhouni will step down in July. He was a steady hand at Sanofi amid tumultuous leadership transitions, but his tenure was marked by hits and misses.

Leadership Research and Development Strategies

Glenmark Eyes Blockbuster Status For First In-House Biologic

Indian drug firm Glenmark Pharmaceuticals says it’s launching a Phase 2b clinical trial for its first biologic developed in-house, a medicine to treat atopic dermatitis that the company believes may have blockbuster potential.

Research & Development Clinical Trials